Dirençli Gram pozitif bakteriyel enfeksiyonlarinda kullanilan oksazolidinon grubu bir antibiyotik: linezolid

Year 2019, Volume: 1 Issue: 1, 14 - 17, 22.01.2019

Taliha Karakök Sami Kınıklı Salih Cesur

https://doi.org/10.38053/agtd.495940

Abstract

Günümüzde metisiline dirençli Staphylococcus
aureus ve vankomisine dirençli enterokoklar,penisiline dirençli pnömokoklar  gibi dirençli gram pozitif bakteriyel
enfeksiyonların tedavisi önemli bir sorundur. Dirençli gram pozitif bakteriyel
enfeksiyonların tedavisinde kullanılan linezolid oksazolidinon grubunda bir
antibiyotiktir. Etki mekanizması ribozom 50 S ünitesine bağlanarak protein
sentezini inisiasyon fazında inhibe eder. Bakteriostatik etkilidir. En önemli
yan etkisi 4 haftadan uzun süre ile kullanımda hematolojik yan etkilere
(trombositopeni ve anemi) neden olmasıdır. Bu yazıda linezolidin etki
spektrumu, endikasyonları ve yan etkileri özetlenmiştir. 

Keywords

Linezolid, etki spektrumu, endikasyon, yan etkileri

Linezolide, a member of oxazolidinones group antibiotics which is used in resistant Gram positive infections

Abstract

Management of infections
due to resistant gram positive microorganisms such as metisilin resistant Staphylococcus aureus, vancomycin
resistant enterococcus, penicillin resistant pneumococcus is a new challenge
for physicians by increasingly rates of antibiotic resistance. Linezolid which
is an agent used for the treatment of these resistant gram positive bacterial
infections is a member of oxazolidinones. The mechanism of action is involving inhibition of the
initiation of bacterial protein synthesis coupling ribosomal 50 S unit. It is
bacteriostatic against most bacteria. The most important adverse effect is
hematologic toxicity (thrombocytopenia and anemia) especially in longer usage
more than four weeks. Antimicrobial spectrum, clinical use and adverse effects
of linezolid is summarized in this review.

 

Keywords

Linezolide, spectrum of antimicrobial activity, indication, side effects

References

• 1. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-42.
• 2. Diekema D, and Jones R. Oxazolidinone antibiotics. Lancet 2001; 358: 1975-81.
• 3. Ager A, and Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist 2012; 5: 87-10.
• 4. Larruskain J, Idigoras P, Marimón JM, et al. Susceptibility of 186. Antimicrob Agents Chemother 2011; 55: 2995-8.
• 5. Ashtekar DR, Costa-Periera R, Shrinivasan T, et al. Oxazolidinones, a new class of synthetic antituberculosis agent: in vitro and in vivo activities of DuP-721 against. Diagn Microbiol Infect Dis 1991; 14: 465-71.
• 6. Fines M, Leclercq R. Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000; 45: 797-802.
• 7. Willke A, Doganay M, Söyletir G, Nobel Kitabevi, İstanbul, 2008; cilt 1: 337-41.
• 8. Meka VG, and Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis 2004; 39: 1010-5.
• 9. Stalker DJ, and Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-40.
• 10. Zyvox® (linezolid) [package insert]. New York: Pharmacia and Upjohn Company, 2012.
• 11. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49: 2260-6.
• 12. Dennis, L. Stevens, Lempiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34: 1481-90.
• 13. Yue J, Dong BR, Yang M, Chen X, Wu T, Liu G. Linezolid versus vancomycin for skin and soft tissue infections. status and date: Edited (no change to conclusions), published in 2016: Iss 1.
• 14. Wunderink RG, Cammarat SK, Oliphant T, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Therapeutics 2003; 25: 980-92.15. Rubinstein E, Cammarat SK, Oliphant TH, Wunderink RG. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-12.
• 16. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: 2-Volume Set, 8e, 2015.
• 17. Lee M, Lee J, Carrol MW, et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. New Eng J Med 2012; 67: 1508-18.
• 18. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents a Chemother 2002; 46: 2723-6.
• 19. Nukui Y, Hatakayema S, Okamoto K, et al. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia. J Antimicrob Chemother 2013; dkt133.
• 20. Takahashi Y, Takesue Y, Nakajima K, et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011; 17: 382-7.
• 21. Jones SL, Athan E, O'Brien D. Serotonin syndrome due to co-administration of linezolid and venlafaxine. J Antimicrob Chemother 2004; 54: 289-90.
• 22. Bernard L, Stern R, Lew D, Hoffmeyer P. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Iinfect Dis 2003; 36: 1197.
• 23. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis 2004; 4: 528-31.
• 24. Lee E, Burger S, Melton C, mullen M, Warren F. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis 2003; 37: 1389-91.